About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
PGNX - Progenics Pharmaceut...| Previous Close | $4.10 | Open | |
| Volume | Market Cap | 355.04M | |
| Yield | Last Dividend |
| Progenics Pharmaceuticals Announces Firs... | 05/07/20 |
| Pending Merger with Lantheus Holdings, Inc. for Combination of an Innovative Commercial Life Sciences Company with a Diversified Precision Diagnostics... | |
| Velan Capital Agrees to Support Merger o... | 04/14/20 |
| NORTH BILLERICA, Mass. & NEW YORK--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (???Lantheus???), parent company of Lantheus Medical Imagin... | |
| Lantheus and Progenics Reschedule Their ... | 04/02/20 |
| NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (???Lantheus???), parent company of Lantheus Medical Imaging, Inc. (??... | |
| The Daily Biotech Pulse: FDA Approves Ba... | 02/21/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 20.... | |
| Progenics Pharmaceuticals Provides Updat... | 01/21/20 |
| NEW YORK, Jan. 21, 2020 (GLOBE NEWSWIRE) -- The Board of Directors of Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing??? | |
| Progenics Pharmaceuticals stock soars 29... | 12/23/19 |
| Progenics Pharmaceuticals, Inc. said Monday a late-stage trial of a treatment for prostate cancer met its main goal. The New York-based company said t... | |
| Progenics Pharmaceuticals to Announce an... | 12/22/19 |
| NEW YORK, Dec. 22, 2019 -- Progenics Pharmaceuticals, Inc. , an oncology company developing innovative targeted medicines and artificial intelligence ... | |
| Progenics Pharmaceuticals to Announce an... | 12/22/19 |
| NEW YORK, Dec. 22, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicine... | |
| INVESTIGATION ALERT: The Schall Law Firm... | 12/20/19 |
| LOS ANGELES--(BUSINESS WIRE)---- $PGNX #PGNX--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Progenics Pharmace... | |
| SHAREHOLDER ALERT: Monteverde & Associat... | 12/11/19 |
| NEW YORK, Dec. 11, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headqu... | |
| Short Interest in Progenics Pharmaceutic... | 11/12/19 |
| Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) was the target of a large decline in short interest during the month of October. As of October 31st, the... | |
| Progenics Pharmaceuticals, Inc. (PGNX) I... | 10/30/19 |
| With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world pr... | |
| Progenics Highlights Additional Serious ... | 10/23/19 |
| Progenics Pharmaceuticals, Inc. (PGNX) (???Progenics??? or the ???Company???), an oncology company developing innovative targeted medicines and artifi... | |
| Velan Sends Letter to Progenics Stockhol... | 10/22/19 |
| Velan Capital, L.P. (together with the other members of its group, ???Velan??? or ???we???), one of the largest stockholders of Progenics Pharmaceutic... | |
| Progenics Pharmaceuticals Needs a Treatm... | 10/11/19 |
| Progenics Pharmaceuticals, Inc. Pushed Through Questionable Merger with Votes from Directors Who Had Resigned Progenics Agreed to Large Termination Fe... | |
| Possible M&A Surrounds These 3 Stocks | 10/04/19 |
| Merger and Acquisition activity, or M&A, is at multi-year lows. Transaction volume has dried up thanks to business uncertainty around tariffs, trade t... | |
| Lantheus To Acquire Progenics Pharma In ... | 10/02/19 |
| Micro-cap biotech Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX ) is advancing strongly following an announcement concerning a buyout deal. The Deal L... | |
| ALERT: Rowley Law PLLC is Investigating ... | 10/02/19 |
| NEW YORK , Oct. 2, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) and i... | |
| Progenics's stock drops after all-stock ... | 10/02/19 |
| Shares of Progenics Pharmaceuticals Inc. dropped 5.5% in premarket trading Wednesday, even though the cancer treatment developer agreed to be acquired... | |
| Could The Progenics Pharmaceuticals, Inc... | 08/09/19 |
| Every investor in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) should be aware of the most powerful shareholder??? | |
| Following These 2 Small-Caps Into Earnin... | 07/19/19 |
| I'm looking forward to hearing from Progenics Pharmaceuticals and Builders FirstSource???.NFLX | |
| Progenics: Joining The Tired Ranks Of In... | 05/14/19 |
| No summary available. | |
| Progenics Pharmaceuticals (PGNX) Q1 2019... | 05/10/19 |
| PGNX earnings call for the period ending March 31, 2019. | |
| Progenics Pharmaceuticals, Inc. (PGNX) C... | 05/09/19 |
| Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Q1 2019 Earnings Conference Call May 09, 2019 08:30 AM ET Company Participants Melissa Downs - Head of I... | |
| Progenics Pharmaceuticals misses by $0.0... | 05/09/19 |
| No summary available. | |
| Progenics Pharmaceuticals (PGNX) Present... | 05/08/19 |
| No summary available. | |
| Progenics Pharmaceuticals Comments on Ve... | 05/07/19 |
| The Progenics Board of Directors is deeply committed to enhancing value for all shareholders and overseeing the Company???s strategy. The Board recogn... | |
| Progenics: Placing Catalysts Into Contex... | 05/07/19 |
| No summary available. | |
| IBI Research On Progenics: Placing Catal... | 05/07/19 |
| Despite the subpar data regarding 1404 and PyL, Progenics Pharmaceuticals is undergoing strong fundamental developments. | |
| Progenics Pharmaceuticals Issues Stateme... | 05/06/19 |
| Progenics Board Deeply Committed to Enhancing Value for all Shareholders Repeated Efforts to Engage Meaningfully with Velan Rebuffed No Shareholder Ac... | |
| Date | 04/12/2019 (AMC) | Est. (EPS/Rev.) | $1.37 |
| Actual (EPS/Rev.) | $2.5B | EPS (TTM) | $??? |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Trading | Trading | 99.00 % | Follow |
| Biotechnology | Robert Gadimian | 26.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
